Patents by Inventor Matthew E. Voss

Matthew E. Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VINORELBINE DERIVATIVES
    Publication number: 20090088568
    Abstract: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
    Type: Application
    Filed: December 10, 2008
    Publication date: April 2, 2009
    Applicant: AMR TECHNOLOGY, INC.
    Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss
  • Lactams as modulators of chemokine receptor activity
    Patent number: 7338975
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: March 4, 2008
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Percy H. Carter, Matthew E. Voss
  • Vinca derivatives
    Patent number: 7238704
    Abstract: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: July 3, 2007
    Assignee: AMR Technology, Inc.
    Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss
  • Vinorelbine derivatives
    Patent number: 7235564
    Abstract: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: June 26, 2007
    Assignee: AMR Technology, Inc.
    Inventors: Ian L. Scott, Jeffrey M. Ralph, Matthew E. Voss
  • Cyclic ?-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-?
    Patent number: 6984648
    Abstract: The present application describes novel cyclic ?-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-? inhibitors.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Jr., Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Spiro-cyclic ?-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-? converting enzyme (TACE)
    Patent number: 6962938
    Abstract: The present application describes novel spiro-cyclic ?-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), and/or aggrecanase inhibitors.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: November 8, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme (TACE)
    Patent number: 6884806
    Abstract: The present application describes novel bicyclic lactam derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein A, B, C, D, R1, and R2 are defined in the present specification, which are useful as metalloprotease, TNF-?, and/or aggrecanase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: April 26, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carl P. Decicco, Ying Song, Jingwu Duan, Matthew E. Voss
  • Lactams as modulators of chemokine receptor activity
    Publication number: 20040186143
    Abstract: The present application describes modulators of MCP-1 of formula (I): 1
    Type: Application
    Filed: February 11, 2004
    Publication date: September 23, 2004
    Inventors: Percy H. Carter, Matthew E. Voss
  • Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20040162426
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE)
    Publication number: 20040132693
    Abstract: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: December 18, 2003
    Publication date: July 8, 2004
    Applicant: Bristol-Myers Squibb Pharma Company
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Spiro-cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; converting enzyme (TACE)
    Patent number: 6720329
    Abstract: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: April 13, 2004
    Assignee: Bristol-Myers Squibb Pharma
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20030181438
    Abstract: The present application describes novel bicyclic lactam derivatives of formula I: 1
    Type: Application
    Filed: October 16, 2002
    Publication date: September 25, 2003
    Inventors: Carl P. Decicco, Ying Song, Jingwu Duan, Matthew E. Voss
  • Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE)
    Publication number: 20030087882
    Abstract: The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: March 12, 2002
    Publication date: May 8, 2003
    Inventors: Gregory R. Ott, Xiao Tao Chen, Jingwu Duan, Matthew E. Voss
  • Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
    Publication number: 20030073682
    Abstract: The present application describes novel substituted aryl hydroxamic acids of formula I: 1
    Type: Application
    Filed: April 3, 2002
    Publication date: April 17, 2003
    Inventors: Matthew E. Voss, Carl P. Decicco, Ruth R. Wexler
  • &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr;
    Patent number: 6495565
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, X, Z, Ua, Xa, Ya, Za, R1, R2, R3, R4, and R4a are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: December 17, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Jr., Matthew E. Voss
  • Cyclic sulfonamide derivatives as metalloproteinase inhibitors
    Patent number: 6455522
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings ring B is a 4-8 membered cyclic sulfonamide containing from 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: September 24, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jingwu Duan, Lihua Chen, Robert J. Cherney, Carl P. Decicco, Matthew E. Voss
  • Substituted aryl hydroxamic acids as metalloproteinase inhibitors
    Patent number: 6365587
    Abstract: The present application describes novel substituted aryl hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: April 2, 2002
    Inventors: Matthew E. Voss, Carl P. Decicco, Ruth R. Wexler
  • Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20020016336
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: March 16, 2001
    Publication date: February 7, 2002
    Inventors: Jingwu Duan, Gregory R. Ott, Lihua Chen, Carl Decicco, Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue
  • Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha
    Publication number: 20020013341
    Abstract: The present application describes novel &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: March 16, 2001
    Publication date: January 31, 2002
    Inventors: Jingwu Duan, Bryan W. King, Carl Decicco, Thomas P. Maduskuie, Matthew E. Voss
  • Neurotransmitter releasers useful for cognition enhancement
    Patent number: 5532247
    Abstract: Compounds of Formula I have been shown to enhance the release of the neurotransmitter acetylcholine and thus may be useful in the treatment of diseases learning and cognition.The compounds of this invention are ##STR1## where Q is ##STR2## A and B are independently selected from H, R.sup.4, --OH and --OCOR.sup.4, orA and B together form .dbd.O, .dbd.S, .dbd.CH.sub.2, .dbd.CHR.sup.4, .dbd.C(R.sup.4), .dbd.NOH, .dbd.NOR.sup.4, 1,3-dioxane, 1,3-dioxolane, 1,3-dithiane or 1,3-dithiolane;R.sup.1 is 4-,3-, or 2-pyridyl, 2-fluoro-4-pyridyl or 3-fluoro-4-pyridyl;R.sup.3, R.sup.4 and R.sup.5 are herein defined;and physiologically suitable salts thereof.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: July 2, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Wendell W. Wilkerson, Richard A. Earl, Matthew E. Voss